112 related articles for article (PubMed ID: 24798718)
1. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Maftouh M; Avan A; Funel N; Paolicchi E; Vasile E; Pacetti P; Vaccaro V; Faviana P; Campani D; Caponi S; Mambrini A; Boggi U; Cantore M; Milella M; Peters GJ; Reni M; Giovannetti E
Pharmacogenomics; 2014 Apr; 15(5):609-18. PubMed ID: 24798718
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
4. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Toll AD; Dasgupta A; Potoczek M; Yeo CJ; Kleer CG; Brody JR; Witkiewicz AK
Hum Pathol; 2010 Sep; 41(9):1205-9. PubMed ID: 20573371
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
7. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
Sun Y; Ren D; Zhou Y; Shen J; Wu H; Jin X
Cell Death Dis; 2021 Sep; 12(10):878. PubMed ID: 34564701
[TBL] [Abstract][Full Text] [Related]
8. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
9. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
Hasegawa S; Nagano H; Konno M; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Wada H; Hama N; Kawamoto K; Marubashi S; Nishida N; Koseki J; Mori M; Doki Y; Ishii H
Int J Oncol; 2016 Jan; 48(1):145-52. PubMed ID: 26648239
[TBL] [Abstract][Full Text] [Related]
10. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
12. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
14. EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.
Kuroki H; Hayashi H; Okabe H; Hashimoto D; Takamori H; Nakahara O; Nakagawa S; Fukushima Y; Chikamoto A; Beppu T; Hirota M; Iyama K; Baba H
PLoS One; 2014; 9(8):e100904. PubMed ID: 25084021
[TBL] [Abstract][Full Text] [Related]
15. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2.
Nakahara O; Takamori H; Iwatsuki M; Baba Y; Sakamoto Y; Tanaka H; Chikamoto A; Horino K; Beppu T; Kanemitsu K; Honda Y; Iyama K; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S565-71. PubMed ID: 21932133
[TBL] [Abstract][Full Text] [Related]
16. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
[TBL] [Abstract][Full Text] [Related]
17. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
[TBL] [Abstract][Full Text] [Related]
18. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY
Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
